Alnylam Announces U.S. Food and Drug Administration …
CAMBRIDGE, Mass., November 25, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug …
Alnylam Pharmaceuticals Press Release | Nov 25, 2024 | Alnylam ...
Nov 25, 2024 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through …
Alnylam Announces U.S. Food and Drug Administration …
Nov 25, 2024 · Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration has accepted for review the Company’ …
Press Releases - Alnylam Pharmaceuticals, Inc.
Oct 9, 2024 · Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with …
Alnylam Shares Surge 30% After Rare Heart Disease Drug Success - Forbes
Jun 24, 2024 · Alnylam said Monday that vutrisiran, an experimental drug for treating a rare condition called transthyretin amyloid cardiomyopathy (ATTR-CM), reduced deaths by all …
Alnylam® Newsroom
Visit our social channels to learn more about the innovative work we are doing at Alnylam.
Articles | Alnylam® Newsroom
Sep 10, 2024 · April 26, 2024 Better Together: Alnylam and Organized Customer Health Systems Want to Improve Access and ... Alnylam's Head of Strategic Accounts discusses the rise of the …
Taking RNAi from interesting science to impactful new treatments
May 13, 2024 · Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
FDA accepts Alnylam’s sNDA for vutrisiran for ATTR-CM treatment
Nov 25, 2024 · Alnylam (ALNY) Pharmaceuticals announced that the U.S. Food and Drug Administration or FDA, has accepted for review the Company’s supplemental New Drug …
Alnylam Submits Supplemental New Drug Application (sNDA) to …
CAMBRIDGE, Mass., October 09, 2024 -- (BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of …